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ABSTRACT
Mitochondrial Lon protease (Lon) regulates several mitochondrial functions, 
and is inhibited by the anticancer molecule triterpenoid 2-cyano-3, 12-dioxooleana-
1,9(11)-dien-28-oic acid (CDDO), or by its C-28 methyl ester derivative (CDDO-Me). To 
analyze the mechanism of action of triterpenoids, we investigated intramitochondrial 
reactive oxygen species (ROS), mitochondrial membrane potential, mitochondrial 
mass, mitochondrial dynamics and morphology, and Lon proteolytic activity in 
RKO human colon cancer cells, in HepG2 hepatocarcinoma cells and in MCF7 
breast carcinoma cells. We found that CDDO and CDDO-Me are potent stressors for 
mitochondria in cancer cells, rather than normal non-transformed cells. In particular, 
they: i) cause depolarization; ii) increase mitochondrial ROS, iii) alter mitochondrial 
morphology and proteins involved in mitochondrial dynamics; iv) affect the levels of 
Lon and those of aconitase and human transcription factor A, which are targets of Lon 
activity; v) increase level of protein carbonyls in mitochondria; vi) lead to intrinsic 
apoptosis. The overexpression of Lon can rescue cells from cell death, providing an 
additional evidence on the role of Lon in conditions of excessive stress load.
INTRODUCTION
The neoplastic transformation of normal 
cells is a multistep process that is first initiated by 
diverse genetic alterations, then enhanced by several 
oncogenesis-associated cellular stresses, that can be 
observed in many cancer cells [1, 2]. Cancer cells 
develop in a microenvironment where stressors are 
greater than those present in normal cells, and for 
their survival have to activate several anti-stress 
pathways and defense mechanisms. Such pathways 
and mechanisms are sustained by a number of 
nononcogenic proteins, i.e. molecules which do not 
initiate tumorigenesis, but participate in the cell stress 
response, and heighten the survival and proliferation 
of cancer cells [3].
Among these proteins, a main role is played by 
Lon protease (Lon), a molecule highly conserved from 
bacteria to mammals, and that in eukarya is one of 
the quality control proteins within mitochondria [4]. 
It is encoded in the nucleus and it localizes to 
mitochondrial matrix, where controls mitochondrial 
function, especially under oxidative, hypoxic and 
metabolic-stress conditions. Lon recognizes damaged 
and oxidized proteins and mediates their proteolysis, 
acts as a chaperone, and is involved in mitochondrial 
DNA maintenance [5]. Aconitase and mitochondrial 
transcription factor A (TFAM) are known substrates of 
Lon proteolytic activity [6, 7].
Several lines of evidence support a role for Lon 
as a non-oncogenic protein essential for cancer survival. 
First, Lon expression increases in response to several 
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stressors. In hypoxic cells, Lon is up-regulated and 
is responsible for degrading cytochrome c oxidase 
4 subunit 1 (COX4-1) to optimize the efficiency of 
respiration [8]. Similarly, when cells are challenged 
with oxidative stress, Lon is involved in the degradation 
of misfolded, oxidized and carbonylated proteins, 
thereby preventing their accumulation [9, 10]. Second, 
Lon plays a key role in the remodeling of respiratory 
chain complexes during the metabolic reprogramming 
triggered in mitochondria in many cancer cells [11]. 
Knock-down of Lon activates the AMP-activated protein 
kinase (AMPK), which is a crucial regulator of the 
energy homeostasis under metabolic stress [12]. Third, 
Lon down-regulation in cancer cells results in disruption 
of mitochondrial function and structure, reduced 
proliferation, and increased apoptotic cell death [13]. 
Finally, Lon overexpression correlates with cancer cell 
aggressiveness, and indeed Lon is up-regulated in several 
cancer cells, including RKO colon carcinoma, HepG2 
hepatocarcinoma, large cell lymphoma cell lines, Granta 
mantle cell lymphoma cell lines, and ex vivo specimens 
obtained from colon carcinoma and bladder cancer [3, 11, 
13–16]. How Lon expression and functions are regulated 
is not well understood, but targeting its activity in cancer 
cells could represent a novel and valuable therapeutic 
strategy.
The synthetic triterpenoid 2-cyano-3, 12-dioxoo-
leana-1,9(11)-dien-28-oic acid (CDDO), and its C-28 
methyl ester derivative (CDDO-Me), are molecules 
with strong anti-inflammatory and anti-proliferative 
activity [17]. Several mechanisms have been proposed 
for their anticancer effect, such as: i) the formation of 
Michael adducts with reactive nucleophiles, including 
free thiols on target proteins, ii) the inhibition of 
mitogen activated protein kinase (MAPK) [18], 
iii) the induction of apoptosis through the mitochondrial 
pathway [19], and iv) the inhibition of Lon proteolytic 
activity [3]. Both CDDO and CDDO-Me interact 
with Lon and form covalent Lon-CDDO adducts that 
irreversibly inhibit Lon activity, thereby inducing 
mitochondrial protein aggregation [3]. We recently 
demonstrated that shRNA-mediated down-regulation of 
Lon in the human colon carcinoma cells RKO leads to 
impaired mitochondrial structure and function, causing 
apoptotic cell death via mitochondria [13]. Thus, we 
wondered whether treating different human cell lines, 
such as RKO, HepG2 and MCF7, compared to normal 
fibroblasts, with compounds that could have a potential 
interest for cancer treatment, i.e. CDDO or its methyl 
ester derivative, would provide the same effects found 
by shRNA knockdown of Lon. Thus, in human cancer 
cells, we characterized the effects of triterpenoids 
on mitochondria, paying a particular attention to 
membrane potential, mass, morphology, dynamics and 
ROS content.
RESULTS
CDDO and CDDO-Me decrease proliferation, 
induce apoptosis in cancer cells, and increase 
mitochondrial hydrogen peroxide and 
mitochondrial superoxide anion
We first analysed the effects of CDDO and CDDO-
Me on cell growth by culturing RKO, HepG2 and MCF7 
cells in the presence of increasing concentrations of 
these molecules for up to 72 hours. As shown in Figure 
1A and in Supplementary Figure S1A, counting adherent 
cells revealed that a time- and concentration-dependent 
inhibition of cell proliferation was observed either for 
CDDO or for CDDO-Me, for RKO, HepG2 and MCF7 
cells. However, CDDO-Me was much stronger than 
CDDO in inhibiting cell growth in all cell lines.
To investigate the inhibitory mechanisms induced 
by these drugs, we analysed their effects on apoptosis, 
and on mitochondrial functionality and morphology. First, 
we analysed simultaneously apoptosis and production 
of reactive oxygen species (ROS) at the single cell level 
by multicolour flow cytometry. Cells were first loaded 
with mitochondria peroxy yellow 1 (mitoPY1), which 
specifically detects mitochondrial hydrogen peroxide 
(mtH2O2), and then treated for up to 24 hours with 
CDDO or CDDO-Me. Supernatants were collected and 
cells stained with MitoSOX red superoxide indicator 
(MitoSOX), and with annexin-V (AnxV), and TO-PRO-3 
iodide (TOPRO). Early apoptotic cells were those positive 
for AnxV and negative for TOPRO, whereas late apoptotic/
necrotic cells were positive for TOPRO, independently on 
AnxV (Figure 1B). Also in this case, CDDO-Me was more 
potent than CDDO in causing cell death for RKO, HepG2 
and MCF7 cells (Figure 1C and 1D, and Supplementary 
Figure S1B, and S1D): a slight increase in cell death was 
observed after 6 hour incubation with CDDO and 1–2.5 
μM CDDO-Me. In RKO cells, after 16 and 24 hours of 
incubation, both CDDO and CDDO-Me led to a strong 
increase in the percentage of early apoptotic cells (Figure 
1C and 1D, left panels). Concerning HepG2 cells, higher 
concentrations of CDDO and CDDO-Me were needed to 
induce apoptosis (Supplementary Figure S1B and S1C). We 
also investigated whether triterpenoids could affect viability 
of normal cells. Thus, we obtained primary cultures of 
human fibroblasts and we treated these cells with increasing 
concentrations of CDDO and CDDO-Me for 6, 16 and 24 
hours. We found that CDDO and CDDO-Me did not cause 
apoptosis in human fibroblasts, except for the highest tested 
concentration of CDDO-Me, and only after 16 and 24 hours 
of incubation (Supplementary Figure S2A and S2B).
We next examined the effects of CDDO and 
CDDO-Me on the activation of caspase-9 and caspase-3, 
to understand if apoptotic cell death was mediated by the 
intrinsic pathway. As shown in Figure 1E, we were able 
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Figure 1: CDDO and CDDO-Me are anti-proliferative and induce apoptosis in RKO cells. A. Growth curve of RKO cells 
incubated with the indicated concentrations of CDDO (left panel) or CDDO-Me (right panel) for up to 72 hours; DMSO-treated cells 
were considered as controls (Ctrl). B. Representative flow cytometric dot plots combining Annexin-V (AnxV) Alexa Fluor Pacific Blue 
and TO-PRO-3 iodide (TOPRO) staining in RKO cells treated with DMSO (Ctrl), or with increasing concentrations of CDDO or CDDO-
Me for 24 hours. C. Percentage of early apoptotic cells (AnxV+/TOPRO- cells) and late apoptotic/necrotic cells (AnxV-/TOPRO+ and 
AnxV+/TOPRO+ cells) after treatment with the indicated concentrations of CDDO for up to 24 hours. Values represent the mean ± SD of 
five independent experiments, *P < 0.05 and **P < 0.01 vs. Ctrl. D. Percentage of early apoptotic cells and late apoptotic/necrotic cells 
after treatment with the indicated concentrations of CDDO-Me for up to 24 hours. Values represent the mean ± SD of five independent 
experiments, *P < 0.05 and **P < 0.01 vs. Ctrl. (Continued )
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Figure 1: (Continued ) CDDO and CDDO-Me are anti-proliferative and induce apoptosis in RKO cells. E. Western blot 
analyses showing caspase-9 activation in RKO cells after treatment with CDDO and CDDO-Me at the indicated concentrations. Cells 
treated with 1 μM staurosporine (STS) for 4 hours were used as positive controls for caspase-9 activation. F. Representative histograms 
showing MitoSOX Red Superoxide Indicator (mitoSOX) and Mitochondria Peroxy Yellow 1 (mitoPY1) to detect mitochondrial anion 
superoxide and mitochondrial hydrogen peroxide in living cells (i.e., those that were AnxV-/TOPRO- cells, indicated by the square). H2O2 
was used as positive control. G. Quantification of mitochondrial hydrogen peroxide (mtH2O2) and mitochondrial anion superoxide (mtO2−) 
in RKO cells treated with CDDO up to 24 hours. Data are expressed as percentage of increase in median fluorescence intensity (MFI) and 
represent the mean ± SD of four independent experiments; *P < 0.05 and **P < 0.01 vs. Ctrl. H. Quantification of mtH2O2 and mtO2− in 
RKO cells treated with CDDO-Me for up to 24 hours. Data are expressed as percentage of increase in MFI and represent the mean ± SD of 
four independent experiments; *P < 0.05 and **P < 0.01 vs. Ctrl.
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to detect both the activation of caspase-9, evidenced by 
the presence of the band at 39 kDa, and the decreased 
expression of the full length protein (47 kDa), at least after 
24 hours of treatment with CDDO-Me. The concentration 
of 2.5 μM CDDO or CDDO-Me led to the activation of 
caspase-9, which occurred after 6-hours treatment in RKO 
cells. As reported in Supplemetary Figure 3A, activated 
caspase-3/7 was detected by flow cytometry and showed 
a major increase after 16 and 24 hours of treatment, both 
for CDDO and CDDO-Me (Supplementary Figure S3B).
Concerning ROS, the gating strategy is reported 
in Figure 1F. Here, we reported a representative dot plot 
showing AnxV and TOPRO fluorescences to discriminate 
viable and dead cells, together with the histograms 
showing mitoPY1 and mitoSOX fluorescences in AnxV-/
TOPRO- cells indicating the content of mtH2O2 and mtO2
− 
in living cells. In this figure, RKO cells were treated with 
H2O2, a molecule known to induce oxidative stress. The 
quantification of mitoPY1 and mitoSOX is reported in 
Figure 1G and 1H for RKO cells, and in Supplementary 
Figure S4A and S4B for HepG2 cells. In RKO cells, when 
CDDO was used, an increase in mtH2O2 and mtO2
− was 
in part observed at 6 hours, but especially after 16 hours 
of incubation (Figure 1G); when CDDO-Me was used, 
mtH2O2 and mtO2
− increased at 2.5 μM after 16 hours of 
incubation (Figure 1H). A slight increase after 24 hours 
of incubation was also observed. In HepG2 cells, CDDO 
led to a two to five-fold increase in mtH2O2 after 6, 16 
and 24 hours of treatment. A parallel increase in mtO2
− 
levels was observed after 6 and 16 hours of incubation 
(Supplementary Figure S4A). When RKO cells were 
treated with CDDO-Me, the increase of mtH2O2 and 
mtO2
− was not observed after 6 hours of treatment but 
only after 16 hours in the presence of 2.5 μM CDDO-
Me (Figure 1G). No change of mtH2O2 and mtO2
− was 
observed in HepG2 cells treated with CDDO-Me 
(Supplementary Figure S4B). We also investigated 
whether triterpenoids could increase mitochondrial ROS 
(mtROS) in non-transformed cells, i.e. primary fibroblasts, 
and we found that CDDO and CDDO-Me induced ROS 
generation but at lower levels compared to RKO and 
HepG2 cells (Supplementary Figure S4C and S4D). While 
in RKO and HepG2 cells after CDDO treatment, mtH2O2 
had a 3- to 5-fold increase, in primary fibroblasts 10 μM 
CDDO was the only concentration able to induce a 1.5-
fold increase of mtH2O2 (Supplementary Figure S4C, left 
panel). A similar, or even lower, increase was observed for 
mtO2
− (Supplementary Figure S4C, right panel).
CDDO and CDDO-Me depolarize mitochondria 
and alter mitochondrial morphology
We then quantified the amount of cells with depolarized 
mitochondria after 24 hours of culture in the presence of 
CDDO or CDDO-Me. In Figure 2A, representative dot 
plots showing JC-1 fluorescence are reported, whereas in 
Figure 2B and Supplementary Figure S5A the quantification 
of cells with depolarized mitochondria is reported for RKO 
and HepG2 cells, respectively. When CDDO was used, 
the concentration of 2.5 μM was sufficient to observe the 
presence of RKO cells with depolarized mitochondria, but 
higher concentrations were required to obtain a similar effect 
in HepG2 cells. Also in this case, CDDO-Me was much 
more potent, since the concentration of 1 μM was sufficient 
to cause a significant increase of cells with depolarized 
mitochondria both in RKO and in HepG2 cells. It is to note 
that concentrations higher than 2.5 μM caused massive 
cell death, so that the measure of mitochondrial membrane 
potential (MMP) had little meaning.
Changes in ROS production and MMP were 
accompanied by alteration of mitochondrial morphology and 
mitochondrial mass. Cells treated with CDDO and CDDO-
Me contained fragmented mitochondria, that were present 
also at 1 μM concentration in all cell lines (Figure 3A and 
Supplementary Figure S5B). The expression levels of 
mitofusin-2 (Mfn2) and Dynamin related protein-1 (Drp1) 
were measured by western blot in lysates of RKO cells 
incubated with different concentrations of CDDO and CDDO-
Me for 6, 16 and 24 hours. In RKO cells incubated with CDDO 
for 6 hours, Drp1 expression increased compared to untreated 
cells (Figure 3B). This increase is statistically significant at 
2.5 μM. On the contrary, Mfn2 expression decreased compared 
to untreated cells especially at high drug concentrations 
(5 and 10 μM; Figure 3B). After 16 and 24 hours of treatment 
at high CDDO concentrations (5 and 10 µM), a significant 
decrease of both Drp1 and Mfn2 expression compared to 
untreated cells (Figure 3B) was found. A partial recovery 
of Drp1 was observed at 10 µM concentration (Figure 3B). 
As far as CDDO-Me treatment is concerned, after 16 and 
24 hours of treatment, Drp1 and Mfn2 expression levels 
decreased in particular at high drug concentrations (1 and 
2.5 μM; Figure 3C).
Both drugs altered mitochondrial mass, in particular 
after 16 and 24 hours of treatment with CDDO both in 
RKO and in HepG2 cells (Figure 3D and Supplementary 
Figure S5C). Slight modifications in mitochondrial mass 
were observed with CDDO-Me. Similar alterations in 
MMP and mitochondrial morphology were observed in 
MCF7 cells (Supplementary Figure S6A and S6B).
CDDO and CDDO-Me alter the expression of 
Lon targets, and Lon overexpression protect cells 
from apoptosis induced by these molecules
We next examined whether and to what extent 
the level of Lon and of two representative substrates, 
namely human transcription factor A (TFAM) and 
aconitase (Aco2) were modified after treatment with 
CDDO or CDDO-Me. Lon protein levels remained 
almost unchanged (Figure 4A and 4B, left panel); 
a slight reduction of Lon mRNA was observed after 
16 hours of treatment, which was maintained until 
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Figure 2: CDDO and CDDO-Me alter mitochondrial membrane potential (MMP). A. Representative dot plots showing JC-1 
monomers and aggregates in cells treated with DMSO (Ctrl) and increasing concentrations of CDDO or CDDO-Me. Valinomycin (Val) 
was used a positive control for mitochondrial depolarization. B. Quantification of cells with depolarized mitochondria. Values represent the 
mean ± SD of five independent experiments, *P < 0.05 and **P < 0.01 vs. Ctrl.
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Figure 3: CDDO and CDDO-Me affect mitochondrial morphology and mitochondrial dynamics. A. Representative 
immune-fluorescence images showing mitochondria in RKO cells treated with 1 μM and 2.5 μM CDDO and CDDO-Me. Red fluorescence 
represents mitochondria labelled with anti-human mitochondrial protein and with goat anti-rabbit F(ab’)2 Alexa 647. Nuclei were 
counterstained with DAPI. B. Representative western blot of mitofusin 2 (Mfn2) and dynamin related protein 1 (Drp1) in RKO cells treated 
with CDDO up to 10 μM for up to 24 hours. Densitometric data are also reported; values represent the mean ± SD of three independent 
experiments; *P < 0.05 and **P < 0.05 vs. Ctrl (dashed lines). (Continued )
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24 hours (Supplementary Figure S7). Concerning CDDO-Me, 
Lon mRNA showed only a slight reduction after 16 hours of 
treatment with 2.5 μM CDDO-Me. Aco2 protein levels slightly 
decreased after 16 hours incubation with CDDO, whereas 
TFAM protein levels increased after 6 hours of treatment 
and then strongly decreased at the higher concentrations of 
CDDO after 16 and 24 hours of treatment (Figure 4A and 
4B). Similarly, when cells were treated with CDDO-Me, Aco2 
levels did not change, whereas TFAM levels increased after 16 
hours of treatment (Figure 4C and 4D).
Considering that Lon is a stress protein inducible by 
multiple stressors, we asked whether Lon overexpression 
could protect RKO cells from CDDO-induced cell death. 
Thus, we generated a retroviral vector harbouring the 
Figure 3: (Continued ) CDDO and CDDO-Me affect mitochondrial morphology and mitochondrial dynamics.  
C. Representative western blot of Mfn2 and Drp1 in RKO cells treated with CDDO-Me up to 2.5 μM for up to 24 hours. Densitometries 
are also reported; values represent the mean ± SD of three independent experiments; *P < 0.05 and **P < 0.01 vs. Ctrl (dashed line). 
D. Detection of mitochondrial mass in RKO treated with DMSO (Ctrl) and increasing concentrations of CDDO and CDDO-Me for up to 24 
hours, as revealed by flow cytometry. Data are expressed as percentage of increase in median fluorescence intensity (MFI) in comparison 
to Ctrl, set to 100%, and represent the mean ± SD of four independent experiments; **P < 0.01 vs. Ctrl.
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cDNA encoding for Lon protease (pMSCV-Lon), and 
we used this to stably transduce RKO cells. We firstly 
ascertained that cells transduced with pMSCV-Lon 
had increased levels of Lon mRNA and Lon protein. In 
pMSCV-Lon cells, a 3-fold increase and a 2-fold increase 
was observed for Lon mRNA and Lon protein, respectively 
(Figure 5A). We also confirmed that Lon was correctly 
localized to mitochondria in these cells (Figure 5B). When 
treated with CDDO and CDDO-Me, cells overexpressing 
Lon were less prone to undergo apoptosis than control 
cells (Figure 5C). Interestingly, also in this case CDDO-
Me was more effective than CDDO in causing cell death.
CDDO and CDDO-Me increase the levels of 
mitochondrial protein carbonyls
As protein carbonylation is the main protein modification 
that takes place as consequence of severe oxidative stress, 
we investigated whether the increase in mtROS observed in 
RKO cells treated with CDDO and CDDO-Me determined 
Figure 4: Effects of CDDO and CDDO-Me on the expression of Lon protease and its proteolytic targets.  
A. Representative western blots of Lon, human mitochondrial transcription factor A (TFAM) and aconitase (Aco2), and TOM20 in RKO 
cells treated with increasing concentrations of CDDO for up to 24 hours. β-actin were used as loading control. B. Densitometric analysis 
showing the levels of Lon, TFAM, Aco2 and TOM20 in CDDO-treated cells. Values represent the mean ± SD of three independent 
experiments, *P < 0.05 vs. Ctrl. (Continued )
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an increase in the levels of protein carbonyls in mitochondria. 
Protein carbonylation was assessed in mitochondrial fractions 
by derivatization of carbonyls with 2, 4-dinitrophenylhydrazine 
(DNPH), followed by anti body detection. In Figure 6A a 
representative oxyblot performed on mitochondrial fractions 
from RKO cells treated with 2.5 μM CDDO is reported. 
As expected, the levels of protein carbonyls, as revealed by 
colorimetric assay, were significantly increased (Figure 6B). 
CDDO-Me led to a slight, but non significant increase at the 
highest tested concentration (data not shown).
DISCUSSION
Our previous studies demonstrated that mito-
chondrial Lon protease plays a crucial role in maintaining 
mitochondrial morphology and function in RKO colon 
carcinoma cells [13]. We showed that Lon is up-regulated 
in several cancer cell lines and in tissue samples from 
colorectal carcinoma, and that in RKO cells Lon down-
regulation leads to impaired mitochondrial proteome, 
reduced levels of mitochondrial RNAs, reduced oxygen 
Figure 4: (Continued ) Effects of CDDO and CDDO-Me on the expression of Lon protease and its proteolytic targets.  
C. Representative western blots of Lon, TFAM, Aco2 and TOM20 in RKO cells treated with increasing concentrations of CDDO-Me for 6, 
16 and 24 hours. D. Densitometric analysis showing the levels of Lon, TFAM, Aco2 and TOM20 in cells treated with CDDO-Me. Values 
represent the mean ± SD of three independent experiments, *P < 0.05 vs. Ctrl.
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Figure 5: Overexpression of Lon protects cells from apoptotic cell death induced by CDDO and CDDO-Me. A. Expression 
of Lon mRNA and Lon protein in control cells (pMSCV) and cells overexpressing Lon (pMSCV-Lon). Values represent the mean ± SD of 
five independent experiments, **P < 0.01 vs. Ctrl. B. Representative pseudocolour maps (upper panels; red indicates maximal expression) 
obtained by confocal microscopy after immunostaining cells with anti-Lon antibody. In lower panels, representative confocal microscopy 
images show that Lon is localized to mitochondria in pMSCV-Lon cells. Cells were immunostained with anti-Lon (red) and anti-human 
mitochondria (hMit, green). Nuclei were counterstained with DAPI. C. Percentage of apoptotic cells after treatment with CDDO up to 
10 μM, and CDDO-Me up to 2.5 μM. Values represent the mean ± SD of five independent experiments, *P < 0.05 vs. Ctrl.
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Figure 6: CDDO and CDDO-Me increased mitochondrial protein carbonyls. A. Detection of protein carbonyls in mitochondrial 
lysates, as revealed by oxyblotting by using a primary antibody against dinitrophenyl hydrazone (DNP). RKO cells were treated with 
2.5 μM CDDO for 16 hours. B. Quantification of protein carbonyls in mitochondrial fractions from RKO cells treated with CDDO at 
different concentrations for 16 hours, as revelaed by colorimetric assay. Values represent the mean ± SD of three independent experiments, 
*P < 0.05 and **P < 0.01 vs. Ctrl. C. Schematic representation of the possible mechanisms linking CDDO and CDDO-Me to cell death.
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consumption rate, increased ROS and fragmented shape 
of mitochondrial network. In these cells, apoptotic cell 
death occurred by the intrinsic pathway, with release of 
cytochrome c in the cytosol, and activation of caspase-9 
and PARP. These features potentially place Lon among 
non-oncogenic proteins, that is those proteins which 
do not initiate tumourigenesis, but are important for 
cancer cell survival. For this reason, the current study 
was aimed at determining the effects of two inhibitors 
of Lon proteolytic activity, the triterpenoids CDDO and 
CDDO-Me, in different cancer cells. In recent years, the 
pharmacologic action of CDDO and CDDO-Me gained 
increased attention, and several studies reported their 
antiproliferative and anticancer activities. We confirmed 
that CDDO and CDDO-Me inhibited cell growth in a 
concentration-dependent manner and induced apoptosis 
in RKO, HepG2 and MCF7 cells. In particular, the fact 
that apoptosis mediated by CDDO and CDDO-Me was 
identified by an increase in phosphatidylserine exposure, 
and by the activation of caspase-3, together with the 
activation of caspase-9, places these triterpenoids among 
molecules able to exert toxic effects on mitochondria.
As previous studies have shown that triterpenoids 
induce apoptosis as a consequence of ROS generation 
[20, 21], we analysed mitochondrial redox state and 
MMP. We found that CDDO leads to increased mtH2O2 
and mtO2
− production, particularly after 16 hours of 
treatment, and determines an increase of carbonylated 
mitochondrial proteins. The capability of this agent to 
increase oxidative stress could be direct, for instance 
through the interaction with electron transport chain 
complexes, or indirect, through the inhibition of Lon, 
which protects mitochondria from stresses and from the 
accumulation of oxidized and carbonylated proteins. 
Complexes I and III of the mitochondrial electron 
transport chain are major sites where superoxide is 
generated, either in the matrix (Complex I and III), or in 
the intermembrane space (Complex III) [22]. Superoxide 
can be partially converted into hydrogen peroxide, which 
can be scavenged by antioxidant systems, including 
catalase, peroxiredoxins and glutathione [23]. When ROS 
accumulate, they can oxidize proteins in a process known 
as protein carbonylation, which is the irreversible, metal-
catalyzed oxidative attack on the side chains of precise 
aminoacids [24]. If not degraded, carbonylated proteins 
form high-molecular-weight cytotoxic aggregates. As Lon 
is responsible for degradation of carbonylated proteins in 
mitochondrial matrix, the increase of carbonylated proteins 
could be likely due to the sum of two concomitant effects 
of CDDO and CDDO-Me: the capability to increase the 
levels of mtROS, which in turn determines mitochondrial 
protein carbonylation, and the inhibition of Lon, which is 
responsible for the degradation of carbonylated proteins. 
Thus, the pro-apoptotic and cytotoxic activity of these 
two triterpenoids can be due to the direct effect of ROS, 
which are pro-apoptotic per se, to damage induced by 
ROS on mt proteins, and to the inhibition of Lon that 
lowers the removal of cytotoxic protein aggregates within 
mitochondria.
Cancer cells produce higher levels of ROS than 
normal cells [25, 26]. On the one hand, these ROS play 
an important role in cancer progression by stimulating 
cell growth and genetic instability. On the other, they 
generate an intrinsic oxidative stress which renders cells 
highly dependent on antioxidant systems and/or highly 
sensitive to agents that dysregulate redox status. For 
instance, the association of 2-methoxyestradiol (2-ME), 
which inhibits superoxide dismutase, to arsenic trioxide, 
which causes ROS increase, has a strong cytotoxic activity 
in leukemia cells [27]. Similarly, hydrogen peroxide and 
2-ME can induce oxidative stress that leads to apoptotic 
and autophagic cell death in transformed cells but not in 
normal, non-transformed cells [28]; finally, β-phenylethyl 
isothiocyanate selectively kills cancer cells through a 
ROS-mediated mechanism [29]. Our data indicate that 
CDDO and CDDO-Me exert a similar effect, as they 
increase mitochondrial oxidative stress, which contributes 
to apoptotic cell death in cancer cells, but fail to induce 
mtROS increase and apoptosis in normal fibroblasts. We 
observed that CDDO and CDDO-Me severely altered 
mitochondria of RKO, HepG2 and MCF7 cells, without 
deeply affecting the levels of Lon protein and mRNA, the 
levels of the main substrates of Lon proteolytic activity 
(except for TFAM), and the levels of proteins involved 
in mitochondria fusion and fission, except for the highest 
concentrations of CDDO and CDDO-Me.
Mitochondrial morphology is regulated by the 
balance of two continuous antagonistic processes: 
fusion and fission [30]. Under physiological conditions, 
mitochondria are elongated and filamentous, but they 
undergo extensive fragmentation during apoptosis. 
It is generally believed that increased mitochondrial 
fragmentation signals cellular damage and initiates 
apoptotic death of the cell and that an unbroken fusion 
process, on the other hand, may lead to uncontrolled 
proliferation [31]. As vital determinants of fission-fusion 
balance, Drp1 and Mfn2 share a reciprocal relationship. 
Factors perturbing this balance are likely to also skew the 
stoichiometric relationship between these two proteins 
[32]. Apoptotic fission is associated with remodeling of 
the cristae, which is characterized by the opening of their 
tubular junction and release of proapoptotic factors, such 
as cyt c, which is required in the cytosol for the activation 
of downstream effector caspases [33]. In RKO cells, after 
6 hours of treatment the Drp1/Mfn2 ratio increased and 
this unbalance might promote mitochondrial fragmentation 
and stimulate apoptotic death that is highlighted after 
16 and 24 hours of treatment. After 16 hours of treatment 
Drp1 and Mfn2 expression levels decreased in particular 
at high drug concentrations (5 and 10 μM). Nevertheless, 
Drp1/Mfn2 ratio remained unbalanced towards fission. 
At 24 hours of treatment Drp1 and Mfn2 expression 
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decreased in particular at high concentrations of CDDO. 
The reduced expression level of these proteins might 
be the consequence of no more fully sustained de novo 
protein synthesis at these high drug concentrations and 
can explain the disruption of mitochondria in terms of 
morphology. In fact, Mfn2 is essential for maintaining 
mitochondrial shape and integrity and alteration of 
protein synthesis of Drp1 may alter mitochondrial 
turnover (mitophagy) [30]. A partial recovery of Drp1 was 
observed at 10 μM concentration after 16 and 24 hours 
of incubation. This result may be explained as the last 
attempt of the cells to increase mitochondrial functionality 
by activating mitochondrial fission and mitochondrial 
turnover to remove mitochondrial cytotoxic protein 
aggregates. High CDDO concentration (10 μM) may 
inhibit Lon protease and increase protein aggregates. In the 
presence of CDDO-Me, again, the reduced expression of 
Drp1 and Mfn2 might be the consequence of no more fully 
sustained de novo protein synthesis and can explain the 
disruption of mitochondrial morphology. No increase of 
Drp1 expression was observed in CDDO-Me treated cells. 
It can be envisioned that mitochondrial fragmentation and 
apoptosis in CDDO-Me treated cells might be activated 
by a different mechanism such as the increase of another 
fission protein like Fis1 [34] or the depletion of another 
fusion protein like OPA1 [35].
Strong differences were observed in the effects 
of CDDO and CDDO-Me on oxidative stress and 
mitochondrial mass. In our models, CDDO induced 
a burst of ROS specifically in mitochondria, which 
resulted in mitochondrial damage, collapse of MMP, 
mitochondrial mass increase and cell death by intrinsic 
apoptosis. Conversely, CDDO-Me was not associated 
with mtROS increase (at least not in a concentration- 
and time-dependent mechanisms as was for CDDO); 
in any case, it induced mitochondrial damage, collapse 
of MMP and apoptotic cell death without altering 
mitochondrial mass. Interestingly, several reports show 
that mitochondrial mass increases in the presence of 
oxidative stress and that such increase depends on 
MMP and protein synthesis in the cytoplasm [36, 37]. 
A similar increase has also been observed in different 
cell types undergoing apoptotic cell death, including 
HepG2, MCF7 and HeLa cells [38, 39]. The reasons 
at the basis of the increase in mitochondrial mass are 
scarcely known, but it is plausible that it could represent 
a response to stress in order to enhance energy supply.
We have found that Lon inhibition by CDDO 
and CDDO-Me alters mitochondrial morphology and 
functionality, and in turn this impairment determines a 
higher production of ROS in mitochondria, and oxidative 
stress. The protein levels of Lon were not strongly 
influenced by CDDO or CDDO-Me treatment whereas 
the levels of TFAM and Aco2 were slightly modulated; 
this indicates that high concentrations are likely able to 
block Lon functions even when this protein is synthetized 
at higher levels, and cells could not avoid loss of 
mitochondrial functionality, accumulation of carbonylated, 
cytotoxic proteins, and cell death.
In conclusion, we have demonstrated that CDDO 
and CDDO-Me act through a pathway that involves 
mitochondria and mitochondria-specific oxidative stress; 
such triterpenoids induce apoptosis in cancer cells, but 
not in normal, non-transformed cells. The association 
between their capability to increase mtROS production 
and to inhibit Lon proteolytic activity probably renders 
these agents good candidates for anticancer therapy 
(Figure 6C). Finally, the fact that the overexpression of 
Lon reduces apoptotic cell death induced by CDDO and 
CDDO-Me indicates that Lon is a key non-oncogenic 
molecule for the maintenance of mitochondria functions 
in cancer cells.
MATERIALS AND METHODS
Cell culture and reagents
RKO cells were cultured in RPMI Glutamax 
supplemented with 10% foetal bovine serum (FBS) 
and gentamycin. HepG2 cells were cultured in MEM 
supplemented with 10% FBS, 1% non essentials 
aminoacids, 1% vitamins, 1% L-glutamine, and 
gentamycin. MCF7 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) Glutamax 
supplemented with 10% FBS and gentamycin. Human 
fibroblasts were obtained after informed and signed 
consent from 1 healthy subject (40 years old) and used 
between 5th and 7th passages. Fibroblasts were isolated 
and established in culture according to standard methods 
[40]. Fibroblasts were grown in 75 cm2 flasks for 5 days 
in DMEM supplemented with 10% FBS, until confluence. 
Then, 1.2 × 105 cells were seeded in 6-well plate and 
treated with CDDO or CDDO-Me when confluent. Cells 
were maintained in 5% CO2 atmosphere at 37°C. CDDO 
and CDDO-Me were purchased from Cayman Chemical 
Company (Ann Arbor, Michigan, USA), were dissolved 
in DMSO and were used at concentrations up to 10 μM. 
All culture media and culture reagents were from Life 
Technologies Corporation (Carlsbad, CA, USA).
Retroviral transduction
The pMSCV-Puro empty vector and the pMSCV 
containing the cDNA encoding for Lon protease (pMSCV-
Lon) were used to transiently transfect amphotrophic 
Phoenix (phxA) cells, and the retroviral transduction has 
been performed as follows. PhxA cells were seeded and 
transfected. Transient transfection was performed by using 
lipofectamine 2000 (Life Technologies Corporation) and 
20 μg of pMSCV-Lon plus 0.9 μg of helper plasmid. PhxA 
cells were maintained in the presence of transfection mix 
for 16 hours, then switched to 20 mL of RKO medium 
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and placed in the incubator for 24 hours. At the end of 
the incubation, the retroviral supernatant was collected, 
filtered with 0.45 μm filter and supplemented with 8 μg/mL 
hexadimethrine bromide, and used to stably transfect RKO 
cells. RKO cells were seeded in 6-well plates at density of 
0.5 × 105 cells/mL. Two mL of retroviral supernatants was 
added to RKO cells that were then centrifuged at 1,800 
rpm at 32°C for 45 minutes. Cells were then placed in the 
32°C incubator. After 2 hours, medium was replaced with 
fresh retroviral supernatants and centrifuged as indicated 
before. Cells were then placed in the 32°C incubator for 
4 hours. At the end of incubation, normal medium was 
added to substitute retroviral supernatant, and cells 
incubated overnight. The day after, normal medium 
was removed and replaced with 4 mL of fresh retroviral 
supernatant, and cells were centrifuged at 1,800 rpm at 32°C 
for 45 minutes. Cells were then put at 32°C for 5 hours, and 
retroviral supernatants was replaced with normal medium. 
After 48 hours, 2 μg/mL puromycin was added to the cells. 
RKO cells which survived the selection were maintained in 
medium supplemented with 1 μg/mL puromycin.
Flow cytometric analysis
The analysis of apoptosis, mitochondrial H2O2 and 
mitochondrial O2
− was performed by staining cells with 
Annexin-V Alexa Fluor Pacific Blue conjugate (AnxV, 
Life Technologies Corporation), TO-PRO-3 iodide 
(TOPRO, Life Technologies Corporation), mitochondria 
Peroxy Yellow 1 (mitoPY1, Sigma Aldrich, St. Louis, 
MO, USA), and MitoSOX Red Superoxide Indicator 
(MitoSOX, Life Technologies Corporation). Cells were 
first loaded with 10 μM mitoPY1 in complete medium 
for 60 minutes and then treated with CDDO or CDDO-
ME for up to 24 hours [41]. As a positive control, cells 
were treated with 1mM H2O2 for 1 hour. At the end of 
the incubation, cells were washed with PBS and incubated 
with 5 μM MitoSOX in complete medium, for 30 minutes 
at 37°C. Then, cells were stained with AnxV in Annexin-V 
binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM 
CaCl2, pH 7.4) for 10 minutes in the dark. TOPRO was 
added before acquisition to assess membrane integrity 
of cells. Samples were analyzed by flow cytometry. In 
particular, cells were first gated on the basis of physical 
parameters. Then, in living cells (AnxV-/TOPRO- cells) 
the median fluorescence intensity (MFI) of mitoPY1 and 
MitoSOX was analysed. The MFI of the unstained sample 
was subtracted to the MFI of the stained sample to avoid 
any influence related to the eventual autofluorescence. 
Then, the net MFI value obtained for control sample was 
set to 100 and other samples calculated according the 
following formula: Relative MFI level = (treated sample 
net MFI / untreated sample net MFI)x100.
Mitochondrial membrane potential was analysed 
by staining cells with 5,5′,6,6′-tetra-chloro-1,1′,3, 
3′-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1, 
Life Technologies Corporation) [42]. Briefly, cells were 
stained with 2.5 μM JC-1 in complete medium, and 
incubated for 10 minutes in the dark; valinomycin was 
used as positive control [43]. Mitochondrial mass was 
evaluated by staining cells with MitoTracker Green (Life 
Technologies Corporation) [44]. Cells were incubated 
with 200 nM MitoTracker Green in culture media for 
30 minutes at 37°C, and then analysed.
The activation of caspase-3 was evaluated by using 
the CellEvent Caspase-3/7 Green Detection Reagent 
(CellEvent, Life Technologies Corporation), which 
consists of a four amino acid peptide, which is intrinsically 
non-fluorescent and emits fluorescence when cleaved by 
caspase-3/7 in apoptotic cells. Briefly, cells were treated 
with CDDO or CDDO-Me. Then, supernatants were 
collected, cells were trypsinized, and stained with 5 μM 
CellEvent for 30 minutes, and then analyzed.
All samples were analysed by using an Attune 
Nxt Acoustic Focusing Cytometer (Life Technologies 
Corporation). The instrument is equipped with a blue laser 
(488 nm), a red laser (637 nm), a yellow laser (561 nm) 
and a violet laser (405 nm) [45]. Data were acquired in 
list mode using Attune Cytometric 2.1 software, and then 
analysed by FlowJo 9.8.5 (Tree Star Inc., Ashland, OR, 
USA) under Mac OSX.
Western blot analysis
Total cellular proteins were obtained by lysing 
cells with RIPA buffer (50 mM Tris, pH 7.5, 0.1% 
Nonidet P-40, 0.1% deoxycholate, 150 mM NaCl, 
4 mM EDTA, and protease inhibitors cocktail). Then, 
10 to 50 μg of total cellular protein or mitochondrial 
fraction, were subjected to SDS-PAGE in 4–12% or 
12% precast gels (Life Technologies Corporation) 
followed by transfer to the proteins onto a nitrocellulose 
membrane (Bio-Rad Laboratories, Hercules, CA, USA) 
and immunoblotting. The following antibodies were 
used: anti-cleaved Caspase-9 (Cell Signaling Technology, 
Danvers, MA, USA), anti-Lon (Primm, Milan, Italy), 
anti-TFAM (Abnova Corporation, Taipei, Taiwan), anti-
Aco2 (Cell Signaling Technology), anti-TOM20 (Santa 
Cruz Biotechnology, Dallas, Texas, USA), anti-MFN2 
(Abnova Corporation, Taipei City, Taiwan), anti-DNM1L 
(Abnova Corporation), goat anti-rabbit IgG (Fc):HRP 
(Serotec, Kidlington, UK). The blot was developed and 
images were captured by using a Chemidoc MP (Bio-
Rad Laboratories). The densitometric analysis was 
performed using ImageLab 5.2.1 (Bio-Rad Laboratories). 
Oxyblot was performed by using the OxyBlot Protein 
Oxidation Detection Kit (Millipore, Billerica, MA, USA), 
following the manufacturer’s instructions. Briefly, cells 
were collected, washed with PBS and resuspended in a 
cytosolic lysis buffer (250 mM sucrose, 70 mM KCl, 137 
mM NaCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4 pH 7.2 
and protease inhibitors) for 5 minutes on ice. Then cells 
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were centrifuged at 1,000 g for 10 minutes at 4°C, and 
the pellet was resuspended in mitochondrial lysis buffer 
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 
2 mM EGTA, 0.2% Triton X-100, 0.03% NP40 and 
protease inhibitors) for 5 minutes on ice. The suspension 
was centrifuged at 10,000 g for 10 minutes at 4°C and the 
supernatant was collected as the mitochondrial fraction. 
Two aliquots (15 μg) of each mitochondrial lysate were 
used: one was subjected to the derivatization reaction 
and the other was incubated with derivatization-control 
solution. Then, samples were loaded in a 4–15% precast 
gel (Bio-Rad Laboratories, Hercules, CA, USA), and 
an anti-DNP antibody was used for the detection of the 
DNPH-derivatized proteins.
Immunofluorescence analysis of mitochondrial 
morphology
Cells were seeded at density of 2 × 105 cells/mL 
on glass coverslips in 6-well plates. After treatment, cells 
were fixed with 4% paraformaldehyde for 10 minutes 
and permeabilised with 0.1% Triton X-100 in phosphate 
buffered saline (PBS) for 5 minutes, and blocked with 
3% bovine serum albumin (BSA) in PBS for 30 minutes, 
at room temperature. Samples were incubated with anti-
human mitochondrial protein (Millipore) in PBS containing 
3% BSA, for 1 hour at room temperature. After washing 
in PBS containing 3% BSA, samples were incubated for 
1 hour at RT with a goat anti-rabbit F(ab’)2 Alexa647 (Life 
Technologies Corporation). After washing in PBS, samples 
were stained with 1 μg/ml 4′,6-diamidino-2-phenylindole 
(DAPI) in PBS for 1 minute, and then mounted with anti-
fading medium (0.21 M 1,4-Diazabicyclo [2.2.2] octane 
(DABCO) and 90% glycerol in 0.02 M Tris, pH 8.0). 
Negative controls were samples not incubated with the 
primary antibody. Then, samples were observed by a Nikon 
A1 confocal laser scanning microscope equipped with 4 
lasers: a 405 nm diode laser for DAPI, a 488 nm argon laser, a 
543 nm HeNe laser and a 637 nm diode laser. The excitation 
and the detection of the samples were carried out in sequential 
mode to avoid overlapping of the two signals. Optical sections 
were obtained at increments of 0.5 μm in the z-axis and were 
digitized with a scanning mode format of 1024 × 1024 pixels 
and 4096 gray levels. Spectral analysis was carried out to 
exclude overlapping between multiple signals. The confocal 
serial sections were processed with ImageJ software to obtain 
three-dimensional projections and image rendering was 
performed by Adobe Photoshop Software.
Measurement of mitochondrial protein 
carbonyls
Protein carbonyls were measured by using the 
Protein Carbonyl Colorimetric Assay Kit (Cayman 
Chemical Company, Ann Arbor, MI, USA) according 
to manufacturer’s instructions. Briefly, 400 μg of 
mitochondrial fraction were used to assay protein 
carbonyls. The carbonyl content was calculated by 
measuring the absorbance at 385 nm was normalized on 
the basis of protein concentration at 280 nm.
Statistical analysis
The results are expressed as the mean ± SD. 
Significance was determined by paired t test, and p < 0.05 
was considered statistically significant.
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